NCT01127542View on ClinicalTrials.gov

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

May 31, 2010

Study Completion Date

December 31, 2011

Conditions
Chronic Lymphocytic Leukaemia
Interventions
DRUG

Lenalidomide

Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.

Trial Locations (9)

BH7 7DW

The Royal Bournemouth Hospital, Bournemouth

B9 5SS

Heart of England NHS Foundation Trust, Birmingham

CB2 0QQ

Addenbrooke's Hospital, Cambridge

CF14 4XW

University Hospital of Wales, Cardiff

LS9 7TF

St James's University Hospital, Leeds

L7 8XP

The Royal Liverpool and Broadgreen University Hospital, Liverpool

SE5 9RS

King's College Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

WF1 4DG

Mid Yorkshire Hospitals NHS Trust, Wakefield

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Leukemia Research Fund

OTHER

lead

The Christie NHS Foundation Trust

OTHER